All News

2018

September

Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More

July

Media Release / Jul 27, 2018

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

June

Media Release / Jun 15, 2018

Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

Read More
Media Release / Jun 01, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab

Read More

May

Media Release / May 24, 2018

Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases

Read More
Media Release / May 02, 2018

Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab

Read More

April

Media Release / Apr 19, 2018

Novartis delivered a strong first quarter and acted to become a more focused medicines company

Read More
Media Release / Apr 18, 2018

Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders

Read More
Media Release / Apr 07, 2018

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

Read More

Pages